Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-31

Study Completion Date

2018-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In a population of patients with non-valvular atrial fibrillation (NVAF), and treated with oral anticoagulants (OAC) in routine clinical practice in England, this study will describe patients treated with each OAC, and to estimate and compare event rates of treatment discontinuation, bleeding, and healthcare resource utilisation (HCRU) across OAC treatments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Risk-Based Screening for the Evaluation of Atrial Fibrillation Trial

NCT03911986

Atrial Fibrillation and Flutter

COMPLETED NA

BEAT AF - Braking Ectopic Atrial Trends In Atrial Fibrillation

NCT05872776

Paroxysmal Atrial Fibrillation

RECRUITING NA

Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation

NCT02608099

Atrial Fibrillation

COMPLETED PHASE4

Responding to AF: Pill-in-Pocket Anticoagulation Guided by Automated Monitoring and Alerts

NCT06922695

Atrial Fibrillation (AF) Atrial Fibrillation (Prevention of Stroke)

RECRUITING NA

Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring

NCT01706146

Atrial Fibrillation

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-valvular Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NVAF patients newly prescribed apixaban

No interventions assigned to this group

NVAF patients newly prescribed rivaroxaban

No interventions assigned to this group

NVAF patients newly prescribed dabigatran

No interventions assigned to this group

NVAF patients newly prescribed VKA

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Have a prescription for apixaban, rivaroxaban, dabigatran, or VKA during the study period
2. Are ≥ 18 years of age at index date
3. Have ≥ 12 months of computerised medical data prior to index date (date of OAC initiation)
4. Have a record of AF on or ever prior to index date

Exclusion Criteria

1. Have a record for a valvular condition that is considered causal for AF on or ever prior to index date
2. Have a history of the OACs which are prescribed during the study period (ie, history of index OAC, as patients need to be newly prescribed either apixaban, rivaroxaban, dabigatran, or VKA)
3. Have more than 1 OAC exposure which starts on the same date

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No